CoChat
Sign Up
Cited by 50CRISPR and Genetic EngineeringRNA regulation and diseaseRNA Interference and Gene Delivery

The double life of CRISPR–Cas13

Open access
Bot, Jorik F, van der Oost, John, Geijsen, Niels·2022·Current Opinion in Biotechnology
DOI 10.1016/j.copbio.2022.102789
Open this paper in CoChat — free accountOpen PDF

Abstract

Since the discovery of RNA-programmable nucleases from the prokaryotic adaptive immune system CRISPR-Cas, these proteins have seen rapid and widespread adoption for biotechnological and clinical research. A recently discovered system, CRISPR-Cas13, uses CRISPR RNA guides to target RNA. Interestingly, RNA targeting by Cas13 results in cleavage of both target RNA and bystander RNA. This feature has been used to develop innovative diagnostic tools for the detection of specific RNAs. Unlike in vitro detection of RNA using collateral RNA cleavage, however, initial studies of mammalian cells only revealed highly specific target RNA-knockdown activity. Although these findings have been confirmed subsequently, several recent publications do report Cas13-mediated toxicity and collateral RNA cleavage when using Cas13 in eukaryotes. Here, we review these conflicting observations and discuss its potential molecular basis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.copbio.2022.102789

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 68

  1. and recommended reading Papers of particular interest, published within the period of review, have been highlighted as: •• of special interest •• of outstanding interest.
  2. Van Der Oost J, Westra ER, Jackson RN, Wiedenheft B: Unravelling the structural and mechanistic basis of CRISPR - Cas systems. Nat Rev Microbiol 2014, 12:479-492.
  3. Marraffini LA: CRISPR-Cas immunity in prokaryotes. Nature (7571) 2015, 526:55-61, https://doi.org/10.1038/nature15386 · DOI
  4. Makarova KS, Wolf YI, Iranzo J, Shmakov SA, Alkhnbashi OS, Brouns SJJ, Charpentier E, Cheng D, Haft DH, Horvath P, et al.: Evolutionary classification of CRISPR-Cas systems: a burst of class 2 and derived variants. Nat Rev Microbiol 2020, 18:67-83.
  5. Shmakov S, Abudayyeh OO, Makarova KS, Wolf YI, Gootenberg JS, Semenova E, Minakhin L, Joung J, Konermann S, Severinov K, et al.: Discovery and functional characterization of diverse Class 2 CRISPR-Cas systems. Mol Cell 2015, 60:385-397.
  6. Shmakov S, Smargon A, Scott D, Cox D, Pyzocha N, Yan W, Abudayyeh OO, Gootenberg JS, Makarova KS, Wolf YI, et al.: Diversity and evolution of class 2 CRISPR-Cas systems. Nat Rev Microbiol 2017, 15:169-182.
  7. Smargon AA, Cox DBT, Pyzocha NK, Zheng K, Slaymaker IM, Gootenberg JS, Abudayyeh OA, Essletzbichler P, Shmakov S, Makarova KS, et al.: Cas13b is a type VI-B CRISPR-associated RNA-guided RNase differentially regulated by accessory proteins Csx27 and Csx28. Mol Cell 2017, 65:618-630.
  8. •• Konermann S, Lotfy P, Brideau NJ, Oki J, Maxim N: Transcriptome engineering with RNA-targeting Type VI-D CRISPR effectors. Cell (3) 2018, 173:665-676, https://doi.org/10.1016/j.cell.2018.02. 033. · DOI · Paper page
  9. Yan WX, Chong S, Zhang H, Makarova KS, Koonin EV, Cheng DR, Scott DA: Cas13d is a compact RNA-targeting Type VI CRISPR effector positively modulated by a WYL-domain-containing accessory protein. Mol Cell (2) 2018, 70:327-339, https://doi.org/ 10.1016/j.molcel.2018.02.028 · DOI
  10. • Xu C, Zhou Y, Xiao Q, He B, Geng G, Wang Z, Cao B, Dong X, Bai W, Wang Y, et al.: Programmable RNA editing with compact CRISPR-Cas13 systems from uncultivated microbes. Nat Methods 2021, 18:499-506.
  11. Cox DBT, Gootenberg JS, Abudayyeh OO, Franklin B, Kellner MJ, Joung J, Zhang F: RNA editing with CRISPR-Cas13. Science 2017, 358:1019-1027.
  12. East-Seletsky A, O'Connell MR, Knight SC, Burstein D, Cate JHD, Tjian R, Doudna JA: Two distinct RNase activities of CRISPR- C2c2 enable guide-RNA processing and RNA detection. Nature 2016, 538:270-273.
  13. East-Seletsky A, O'Connell MR, Burstein D, Knott GJ, Doudna JA, O'Connell MR, Burstein D, Knott GJ, Doudna JA, O'Connell MR, et al.: RNA targeting by functionally orthogonal Type VI-A CRISPR-Cas enzymes. Mol Cell 2017, 66:373-383.e3.
  14. Gootenberg JS, Abudayyeh OO, Lee JW, Essletzbichler P, Dy AJ, Joung J, Verdine V, Donghia N, Daringer NM, Freije CA, et al.: Nucleic acid detection with CRISPR-Cas13a/C2c2. Science 2017, 356:438-442.
  15. Gootenberg JS, Abudayyeh OO, Kellner MJ, Joung J, Collins JJ, Zhang F: Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6. Science 2018, 360:439-444.
  16. Myhrvold C, Freije CA, Gootenberg JS, Abudayyeh OO, Metsky HC, Kellner MJ, Barnes KG, Chak B, Yozwiak NL, MacInnis BL, et al.: Field-deployable viral diagnostics using CRISPR-Cas13. Science 2018, 448:444-448.
  17. Fozouni P, Son S, Derby MD, de L, Knott GJ, Gray CN, D'Ambrosio MV, Zhao C, Switz NA, Kumar GR, Stephens SI, et al.: Amplification-free detection of SARS-CoV-2 with CRISPR- Cas13a and mobile phone microscopy. Cell 2021, 184:323-333.
  18. Arizti-sanz J, Freije CA, Stanton AC, Boehm CK, Petros BA, Siddiqui S, Shaw BM, Adams G, Kosoko-Thoroddsen T-SF, Kemball ME, Uwanibe JN, Ajogbasile FV, Eromon PE, Gross R, Wronka L, Caviness K, Hensley LE, Bergman NH, MacInnis BL, Happi CT, Lemieux JE, Sabeti PC, Myhrvold C: Streamlined inactivation, amplification, and Cas13-based detection of SARS-CoV-2. Nat Commun (5921) 2020, 11, https://doi.org/10. 1038/s41467-020-19097-x · DOI
  19. Patchsung M, Jantarug K, Pattama A, Aphicho K, Suraritdechachai S, Meesawat P, Sappakhaw K, Leelahakorn N, Ruenkam T, Wongsatit T, et al.: Clinical validation of a Cas13-based assay for the detection of SARS-CoV-2 RNA. Nat Biomed Eng (12) 2020, 4:1140-1149, https://doi.org/10.1038/s41551-020-00603-x · DOI
  20. Meeske AJ, Nakandakari-Higa S, Marraffini LA: Cas13-induced cellular dormancy prevents the rise of CRISPR-resistant bacteriophage. Nature (7760) 2019, 570:241-245, https://doi.org/ 10.1038/s41586-019-1257-5 · DOI
  21. Mohanraju P, Saha C, van Baarlen P, Louwen R, Staals RHJ, van der Oost J: Alternative functions of CRISPR-Cas systems in the evolutionary arms race. Nat Rev Microbiol 2022, 20:351-364, https://doi.org/10.1038/s41579-021-00663-z · DOI
  22. Abudayyeh OO, Gootenberg JS, Essletzbichler P, Han S, Joung J, Belanto JJ, Verdine V, Cox DBT, Kellner MJ, Regev A, et al.: RNA targeting with CRISPR-Cas13. Nature (7675) 2017, 550:280-284, https://doi.org/10.1038/nature24049 · DOI · Paper page
  23. Jackson AL, Bartz SR, Schelter J, Kobayashi SV, Burchard J, Mao M, Li B, Cavet G, Linsley PS: Expression profiling reveals off- target gene regulation by RNAi. Nat Biotechnol 2003, 21:635-637.
  24. Smith I, Greenside PG, Wadden D, Tirosh I, Natoli T, Narayan R, Root DE, Golub TR, Subramanian A, Doench JG: Evaluation of RNAi and CRISPR technologies by large-scale gene expression profiling in the Connectivity Map. PLoS Biol 2017, 15:e2003213, https://doi.org/10.1101/147504 · DOI
  25. Stojic L, Lun ATL, Mangei J, Mascalchi P, Quarantotti V, Barr AR, Bakal C, Marioni JC, Gergely F, Odom DT: Specificity of RNAi, LNA and CRISPRi as loss-of-function methods in transcriptional analysis. Nucleic Acids Res 2018, 46:5950-5966.
  26. He B, Peng W, Huang J, Zhang H, Zhou Y, Yang X, Liu J, Li Z, Xu C, Xue M, et al.: Modulation of metabolic functions through Cas13d-mediated gene knockdown in liver. Protein Cell 2020, 11:518-524.
  27. Zhang Y, Nguyen TM, Zhang XO, Wang L, Phan T, Clohessy JG, Pandolfi PP: Optimized RNA-targeting CRISPR/Cas13d technology outperforms shRNA in identifying functional circRNAs. Genome Biol 2021, 22:1-22.
  28. Li S, Li X, Xue W, Zhang L, Yang LZ, Cao SM, Lei YN, Liu CX, Guo SK, Shan L, et al.: Screening for functional circular RNAs using the CRISPR-Cas13 system. Nat Methods 2021, 18:51-59.
  29. Huynh N, Depner N, Larson R, King-Jones K: A versatile toolkit for CRISPR-Cas13-based RNA manipulation in Drosophila. Genome Biol 2020, 21:1-29.
  30. • Wessels HH, Méndez-Mancilla A, Guo X, Legut M, Daniloski Z, Sanjana NE: Massively parallel Cas13 screens reveal principles for guide RNA design. Nat Biotechnol 2020, 38:722-727.
  31. Tambe A, East-seletsky A, Knott GJ, Doudna JA, O'Connell MR: RNA-binding and HEPN-nuclease activation are decoupled in CRISPR-Cas13a. Cell Rep 2018, 24:1025-1036.
  32. Meeske AJ, Marraffini LA: RNA guide complementarity prevents self-targeting in Type VI CRISPR systems. Mol Cell 2018, 71:791-801, https://doi.org/10.1016/j.molcel.2018.07.013 · DOI
  33. Kushawah G, Hernandez-Huertas L, Abugattas-Nuñez del Prado J, Martinez-Morales JR, DeVore ML, Hassan H, Moreno-Sanchez I, Tomas-Gallardo L, Diaz-Moscoso A, Monges DE, et al.: CRISPR- Cas13d induces efficient mRNA knockdown in animal embryos. Dev Cell 2020, 54:805-817.e7.
  34. Zhou H, Su J, Hu X, Zhou C, Li H, Chen Z, Xiao Q, Wang B, Wu W, Sun Y, et al.: Glia-to-neuron conversion by CRISPR-CasRx alleviates symptoms of neurological disease in mice. Cell 2020, 181:590-603.
  35. Wang Q, Liu Y, Han C, Yang M, Huang F, Duan X, Wang S, Yu Y, Liu J, Yang H, et al.: Efficient RNA virus targeting via CRISPR/ CasRx in fish. J Virol 2021, 95:e00461-21.
  36. Jing X, Xie B, Chen L, Zhang N, Jiang Y, Qin H, Wang H, Hao P, Yang S, Li X: Implementation of the CRISPR-Cas13a system in fission yeast and its repurposing for precise RNA editing. Nucleic Acids Res 2018, 46:e90.
  37. Mahas A, Aman R, Mahfouz M: CRISPR-Cas13d mediates robust RNA virus interference in plants. Genome Biol 2019, 20, https:// doi.org/10.1186/s13059-019-1881-2 · DOI
  38. Aman R, Ali Z, Butt H, Mahas A, Aljedaani F, Khan MZ, Ding S, Mahfouz M: RNA virus interference via CRISPR/Cas13a system in plants. Genome Biol 2018, 19:1.
  39. Freije CA, Myhrvold C, Boehm CK, Lin AE, Welch NL, Carter A, Metsky HC, Luo CY, Abudayyeh OO, Gootenberg JS, et al.: Programmable inhibition and detection of RNA viruses using Cas13. Mol Cell (5) 2019, 76:826-837, https://doi.org/10.1016/J. MOLCEL.2019.09.013 · DOI
  40. Tng PYL, Carabajal Paladino L, Verkuijl SAN, Purcell J, Merits A, Leftwich PT, Fragkoudis R, Noad R, Alphey L: Cas13b-dependent and Cas13b-independent RNA knockdown of viral sequences in mosquito cells following guide RNA expression. Commun Biol 2020, 3:413.
  41. Blanchard EL, Vanover D, Bawage SS, Tiwari PM, Rotolo L, Beyersdorf J, Peck HE, Bruno NC, Hincapie R, Michel F, et al.: Treatment of influenza and SARS-CoV-2 infections via mRNA- encoded Cas13a in rodents. Nat Biotechnol 2021, 39:717-726.
  42. Liu L, Li X, Wang J, Wang M, Chen P, Yin M, Li J, Sheng G, Wang Y: Two distant catalytic sites are responsible for C2c2 RNase activities. Cell 2017, 168:121-134.e12.
  43. Zhang C, Konermann S, Brideau NJ, Griffin PR, Hsu PD, Lyumkis D, Zhang C, Konermann S, Brideau NJ, Lotfy P, et al.: Structural basis for the RNA-guided ribonuclease activity of CRISPR- Cas13d article structural basis for the RNA-guided ribonuclease activity of CRISPR-Cas13d. Cell 2018, 175:212-223.e17.
  44. Slaymaker IM, Mesa P, Kellner MJ, Kannan S, Brignole E, Koob J, Feliciano PR, Stella S, Abudayyeh OO, Gootenberg JS, et al.: High- resolution structure of Cas13b and biochemical characterization of RNA targeting and cleavage. Cell Rep 2019, 26:3741-3751.e5.
  45. Knott GJ, East-Seletsky A, Cofsky JC, Holton JM, Charles E, O'Connell MR, Doudna JA: Guide-bound structures of an RNA- targeting A-cleaving CRISPR-Cas13a enzyme. Nat Struct Mol Biol (10) 2017, 24:825-833, https://doi.org/10.1038/nsmb.3466 · DOI
  46. Liu L, Li X, Ma J, Li Z, You L, Wang J, Wang M, Zhang X, Wang Y: The molecular architecture for RNA-guided RNA cleavage by Cas13a. Cell 2017, 170:714-726.e10.
  47. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E: A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 2012, 337:816-821.
  48. Gasiunas G, Barrangou R, Horvath P, Siksnys V: Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proc Natl Acad Sci USA 2012, 109:E2579-E2586.
  49. Zetsche B, Gootenberg JS, Abudayyeh OO, Slaymaker IM, Makarova KSKS, Essletzbichler P, Volz SE, Joung JJK, Van Der Oost J, Regev A, et al.: Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. Cell 2015, 163:759-771.
  50. • Wang Q, Liu X, Zhou J, Yang C, Wang G, Tan Y, Wu Y, Zhang S, Yi K, Kang C: The CRISPR-Cas13a gene-editing system induces collateral cleavage of RNA in glioma cells. Adv Sci 2019, 6:1901299. First description of collateral cleavage by Cas13 in mammalian cells.
  51. Wang L, Zhou J, Wang Q, Wang Y, Kang C: Rapid design and development of CRISPR-Cas13a targeting SARS-CoV-2 spike protein. Theranostics 2021, 11:649-664, https://doi.org/10.7150/ thno.51479 · DOI
  52. Buchman AB, Brogan DJ, Sun R, Yang T, Hsu PD, Akbari OS: Programmable RNA targeting using CasRx in flies. Cris J 2020, 3:164-176.
  53. Shi P, Murphy MR, Aparicio AO, Kesner JS, Fang Z, Chen Z, Trehan A, Wu X: RNA-guided cell targeting with CRISPR/RfxCas13d collateral activity in human cells. bioRxiv 2021,.
  54. • Li Y., Xu J., Guo X., Li Z., Cao L., Liu S., Guo Y., Wang G., Luo Y., Zhang Z., et al.: Collateral cleavage of 28s rRNA by RfxCas13d causes death of mice. bioRxiv 2022.. This paper highlights the potential dangers of unexpected collateral cleavage in therapeutic application of CRISPR-Cas13 as a specific RNA knockdown tool.
  55. • Ai Y, Liang D, Wilusz JE: CRISPR/Cas13 effectors have differing extents of off-target effects that limit their utility in eukaryotic cells. Nucleic Acids Res 2022, 50:1-16. Reports that collateral cleavage depends on target RNA expression, cell type, and the Cas13 ortholog used. The commonly used RfxCas13d showed stronger collateral cleavage than PspCas13b.
  56. • Vialetto E, Yu Y, Collins SP, Wandera KG, Barquist L, Beisel CL: A target expression threshold dictates invader defense and prevents autoimmunity by CRISPR-Cas13. Cell Host Microbe 2022, 30:1151-1162, https://doi.org/10.1016/j.chom.2022.05.013. Shows that the target RNA of Cas13 must be expression above a certain threshold for dormancy induction in bacteria. · DOI
  57. Zhou C, Hu X, Tang C, Liu W, Wang S, Zhou Y, Zhao Q, Bo Q, Shi L, Sun X, et al.: CasRx-mediated RNA targeting prevents choroidal neovascularization in a mouse model of age-related macular degeneration. Natl Sci Rev 2020, 7:835-837.
  58. Xu D, Cai Y, Tang L, Han X, Gao F, Cao H, Qi F, Kapranov P: A CRISPR/Cas13-based approach demonstrates biological relevance of vlinc class of long non-coding RNAs in anticancer drug response. Sci Rep 2020, 10:1-13.
  59. Gao J, Luo T, Lin N, Zhang S, Wang J: A new tool for CRISPR- Cas13a-based cancer gene therapy. Mol Ther -Oncolytics 2020, 19:79-92.
  60. Abbott TR, Dhamdhere G, Liu Y, Lin X, Goudy L, Zeng L, Chemparathy A, Chmura S, Heaton NS, Debs R, et al.: Development of CRISPR as an antiviral strategy to combat SARS-CoV-2 and influenza. Cell 2020, 181:865-876.e12.
  61. Moran MA, Satinsky B, Gifford SM, Luo H, Rivers A, Chan L, Meng J, Durham BP, Shen C, Varaljay VA, et al.: Sizing up metatranscriptomics. ISME J 2012, 7:237-243.
  62. Bartholomäus A, Fedyunin I, Feist P, Sin C, Zhang G, Valleriani A, Ignatova Z: Bacteria differently regulate mRNA abundance to specifically respond to various stresses. Philos Trans R Soc A (2063) 2016, 374, https://doi.org/10.1098/rsta.2015.0069 · DOI · Paper page
  63. Shapiro E, Biezuner T, Linnarsson S: Single-cell sequencing- based technologies will revolutionize whole-organism science. Nature Reviews Genetics (9) 2013, 14:618-630, https://doi.org/10. 1038/nrg3542 · DOI · Paper page
  64. Ahuja D, Sáenz-Robles MT, Pipas JM: SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation. Oncogene 2005, 24:7729-7745.
  65. Tsherniak A, Vazquez F, Montgomery PG, Golub TR, Boehm JS, Hahn WC, Tsherniak A, Vazquez F, Montgomery PG, Weir BA, et al.: Defining a cancer dependency map. Cell 2017, 170:564-570.e16.
  66. • Beljouw SPB, van, Haagsma AC, Rodriguez-Molina A, Berg DF, van den, Vink JNA, Brouns SJJ: The gRAMP CRISPR-Cas effector is an RNA endonuclease complexed with a caspase-like peptidase. Science (6561) 2021, 373:1349-1353, https://doi.org/ 10.1126/science.abk2718. First report describing Cas7-11, a single protein CRISPR effector that only cleaves RNA specifically. Intriguingly, they also describe an inter- action between Cas7-11 and a caspase like protein. · DOI
  67. Rauch S, He C, Dickinson BC: Targeted m 6 A reader proteins to study epitranscriptomic regulation of single RNAs. J Am Chem Soc 2018, 140:11974-11981.
  68. •• Rauch S, He E, Srienc M, Zhou H, Zhang Z, Dickinson BC: Programmable RNA-guided RNA effector proteins built from human parts. Cell (1) 2019, 178:122-134, https://doi.org/10.1016/j. cell.2019.05.049. · DOI

Cited by

Sorted by citations

Authors
Bot, J. F., van der Oost, J., & Geijsen, N.
Affiliations
Leiden University Medical Center (NL)
Corresponding author
Geijsen, Niels
ORCID
Venue
Current Opinion in Biotechnology
Publisher
Elsevier BV
Published
2022-12
Volume
78
Pages
102789
ISSN
0958-1669 (ISSN-L)
DOI
10.1016/j.copbio.2022.102789
OpenAlex
W4295788291
Cited by
50
References
3
Citations by year
2026: 9 · 2025: 15 · 2024: 21 · 2023: 5
FWCI
1.07
Type
journal article
Language
en
Open access
Licence
Locations
  • Current Opinion in Biotechnology (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Socio-Environmental Systems Modeling (submittedVersion, cc-by)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • Leiden Repository (Leiden University) (submittedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion, cc-by)
Funders
Novo Nordisk (NNF21CC0073729)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
CRISPR-Cas13, RNA knockdown, prokaryotic adaptive immunity
MeSH terms
Gene Editing, Animals, Mammals, RNA, CRISPR-Cas Systems

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review